

Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine cancer - able to walk and complete all self care but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- significant cardiovascular disease such as heart failure - hypertension that isn't controlled by medication - uncontrolled diabetes - history of liver cirrhosis

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Gastric Cancer, Neuroendocrine tumors, Pancreas, Pancreatic Cancer, Stomach Cancer

More Information

Description: The main purpose of this the study is to find out if a new investigational drug RYZ101 more effectively treats your cancer than the standard therapy, and to see if it is safe, tolerable, and to learn the pharmacokinetics (PK).

Study Contact: Samantha Schommer - schom217@umn.edu

Principal Investigator: Edward Greeno, M.D.

Phase: PHASE3

IRB

Number: STUDY00021459

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.